# Intravenous Recombinant Human Prourokinase for Acute Medium Vessel Occlusion 4.5-24 Hours After Ischemic Stroke

Study · id `cardio:ct-nct07776873` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT07776873](<https://clinicaltrials.gov/study/NCT07776873>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT07776873

Browse, organ or system: Brain  
Browse, condition area: Stroke  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 616 participants.

## Technical summary

Registry record NCT07776873. Randomized; single masking; primary purpose treatment. Start 2026-10-06 (actual); primary completion 2029-06-30 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; single masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 616 participants (planned count; ClinicalTrials.gov record NCT07776873, source copy `cardio:ctgov-nct07776873-2026-10-07`, retrieved 2026-10-26)
- Started: 2026-10-06 (actual) (ClinicalTrials.gov record NCT07776873, source copy `cardio:ctgov-nct07776873-2026-10-07`, retrieved 2026-10-26)
- Primary completion: 2029-06-30 (anticipated) (ClinicalTrials.gov record NCT07776873, source copy `cardio:ctgov-nct07776873-2026-10-07`, retrieved 2026-10-26)
- Completion: 2029-06-30 (anticipated) (ClinicalTrials.gov record NCT07776873, source copy `cardio:ctgov-nct07776873-2026-10-07`, retrieved 2026-10-26)
- Countries: China (ClinicalTrials.gov record NCT07776873, source copy `cardio:ctgov-nct07776873-2026-10-07`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct07776873-2026-10-07`, retrieved 2026-10-26)

## The registry's words

- Brief title: Intravenous Recombinant Human Prourokinase for Acute Medium Vessel Occlusion 4.5-24 Hours After Ischemic Stroke
- Acronym: HOPE-MeVO
- Condition: Acute Ischemic Stroke
- Intervention (Drug): Recombinant Human Prourokinase for Injection (rhPro-UK)
- Intervention (Other): Standard medical treatment (SMT)
- Lead sponsor: The First Affiliated Hospital of Anhui Medical University
- Lead sponsor class: OTHER

## Connected pages

- Registry condition terms include this condition: Ischemic stroke (`cardio:ischemic-stroke`)
- Registry condition terms include this condition: Stroke (`core:stroke`)
- Registry lists this organization as the lead sponsor: The First Affiliated Hospital of Anhui Medical University (`cardio:org-the-first-affiliated-hospital-of-anhui-medical-university`)

## Provenance

Content hash: 9724301914fe99f32dca328902e554a194d0117d81c39f586af72c5c15244f75
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
